


## CORRIGENDUM

# Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

P. G. Corrie, A. Marshall, P. D. Nathan, P. Lorigan, M. Gore, S. Tahir, G. Faust, C. G. Kelly, M. Marples, S. J. Danson, E. Marshall, S. J. Houston, R. E. Board, A. M. Waterston, J. P. Nobes, M. Harries, S. Kumar, A. Goodman, A. Dagleish, A. Martin-Clavijo, S. Westwell, R. Casasola, D. Chao, A. Maraveyas, P. M. Patel, C. H. Ottensmeier, D. Farrugia, A. Humphreys, B. Eccles, G. Young, E. O. Barker, C. Harman, M. Weiss, K. A. Myers, A. Chhabra, S. H. Rodwell, J. A. Dunn & M. R. Middleton, on behalf of the AVAST-M Investigators

*Ann Oncol* 2018; 29(8): 1843–1852 (doi: 10.1093/annonc/mdy229)

In the original article, there was an error in Figure 3. The figure has now been corrected as below in the online version of the article.

**Figure 3.**